Holly John

Holly John is an influential leader with rich experience in partnering with external stakeholders in the biotech and pharmaceutical industries. She is known for being an innovative and strategic thinker, who achieves exceptional results through strong partnerships with Patient Advocacy and Alliance Organizations. Holly has served as Director of Patient Advocacy for rare diseases, such as Sickle Cell Disease, Alpha-1 Antitrypsin Deficiency and APOL-1 Mediated Kidney Disease with Vertex Pharmaceuticals, Cyclerion Therapeutics and Ironwood Pharmaceuticals.